Medistim — Earnings Release 2025

Feb 27, 2026

Fourth quarter results and preliminary financials for 2025 for Medistim ASA

Fourth quarter results and preliminary financials for 2025 for Medistim ASA

Record sales for both the quarter and year. 20.6% growth in the fourth quarter, ending at NOK 182.3 (MNOK 151.1). 24.4% growth for the year, ending at MNOK 699.8 (MNOK 562.6).

Currency neutral sales of own products were up 25.6 % for the quarter and 28.3 % for the year

Strong currency neutral growth for the quarter in AMERICAS and EMEA, up 44.3% and 24.4% respectively. APAC down 24.2 %, however, up 40.0 % for the year.

Third-party distributor sales in Scandinavia increased 2.2% for the quarter and 12.7% for the Year

Strong operating profit (EBIT) growing by 64.0% to MNOK 42.3 for the quarter, resulting in

23.2% EBIT margin (MNOK 25.8, 17.1% margin). Record EBIT for the year, growing 50.0% to MNOK 196.2, resulting in 28.0% EBIT margin (MNOK 131.1, 23.3% margin).

Recurring sales remained high at 70.1% (73.7%). Strong capital sales reduce recurring sales in % compared to last year.

Solid cash position at quarter end with MNOK 212.1. The company has no interest-bearing bank loans.

The Board of Directors will suggest to the General Assembly a dividend of NOK 8.00 per share, total dividend payment of MNOK 146.2.